Cardiac complications and manifestations of chemotherapy for cancer

Heart

Volumn 100, Issue 14, 2014, Pages 1133-1140

  Khawaja, Muhammed Zeeshan ^a,b   Cafferkey, Catherine ^c   Rajani, Ronak ^b   Redwood, Simon ^a,b   Cunningham, David ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BISOPROLOL; CAPECITABINE; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; EPLERENONE; FLUOROURACIL; HYDRALAZINE; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; PACLITAXEL; PREDNISONE; RAMIPRIL; SPIRONOLACTONE; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VALSARTAN; VINCRISTINE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; NILOTINIB; PREDNISOLONE; RAZOXANE; SORAFENIB; VANDETANIB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; COLON CANCER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY SPASM; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY CANCER; LEUKEMIA; LYMPHOMA; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PERICARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SOLID TUMOR; SYSTOLIC DYSFUNCTION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ACUTE LEUKEMIA; ACUTE PROMYELOID LEUKEMIA; BRADYCARDIA; CANCER PATIENT; CANCER SURVIVAL; CARDIOLOGIST; CLINICAL FEATURE; DRUG POTENCY; HEART DISEASE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEMORRHAGIC MYOPERICARDITIS; HIGH RISK POPULATION; MALIGNANT NEOPLASTIC DISEASE; ONCOLOGIST; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SURVIVAL TIME;

CARDIO-ONCOLOGY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY; HEART FAILURE;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEART DISEASES; HEART FAILURE; HUMANS; HYPERTENSION; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84903375373     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303713     Document Type: Article

References (14)

1. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102-11. ▶ Proposes the type I/II, irreversible/reversible classification of cardiotoxic effects of chemotherapy.
2. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52. ▶ Describes the incidence of early and late cardiotoxic side effects of anthracycline use. (Pubitemid 27167391)
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
4. Hawkes EA, Okines AFC, Plummer C, et al. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011;29:e560 -2.
5. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009;20:1535-42.
6. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-319.
8. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [Internet]. ctep.cancer.gov. 2010 [cited 2013 Aug 23]. http://ctep. cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-40 ▶ The adverse event reporting consensus used in oncology trials. Important to appreciate the difference between cardiac and oncology definitions.
9. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-61. ▶ Interesting results regarding a cardioprotective agent not yet widely recommended in guidelines.
10. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. ▶ Evidence for the use of β-blockers in chemotherapy induced cardiomyopathy. (Pubitemid 44855419)
11. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492-8. (Pubitemid 41691573)
12. Curigliano G, Cardinale D, Suter T, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii155 -66. ▶ The current European Society for Medical Oncology guidelines on the diagnosis, treatment and surveillance of cardiotoxicity.
13. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005;41:1542-6. (Pubitemid 40981835)
14. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;135:842-3. ▶ An important examination of dangerous QTc prolongation caused by one of the only viable treatment options for a fatal condition. (Pubitemid 33051273)